Daré Bioscience Announces Publication In The Journal Of Sexual Medicine, Safety Findings From The Phase 2b RESPOND Clinical Study Of Sildenafil Cream, 3.6%
Portfolio Pulse from Benzinga Newsdesk
Daré Bioscience has published safety findings from its Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% in The Journal of Sexual Medicine. The study shows the cream is safe and well-tolerated, without common side effects like headache and flushing seen in oral sildenafil.
August 26, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Daré Bioscience's publication of safety data for its Sildenafil Cream, 3.6% in a reputable journal supports its development as a treatment for FSAD, potentially boosting investor confidence.
The publication of positive safety data in a reputable journal is a significant milestone for Daré Bioscience, as it supports the ongoing development of their product. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100